Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WX-671 plus gemcitabine vs gemcitabine in unresectable locally advanced pancreatic cancer
2006-005314-12Phase 2Completed
- Sponsor
- Heidelberg Pharma AG
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of upamostat in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Heidelberg Pharma AG. Primary endpoint: Response rate. Started Oct 2006; status: completed.
02
Drugs
upamostat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2006-005314-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005314-12.